Unquestionably, the Most Disappointing Drug Launch of 2016 @themotleyfool #stocks $MRK, $RHHBY, $SRPT, $GILD https://t.co/SFMK9olK2X
Bullish Engulfing https://t.co/CZxCmhnevl $IJH $ARNA $GERN $SRPT $PFE $TJX $SYMC $UTX $EXC $DYN $TNK $CSC $ARNC $HPE $IRWD $PANW $VIAV
$XBI $SRPT let's hope Sanders and Warren do not ruin it with a social media post. Fingers crossed
RT @Shapiro_elyse: Another Duchenne's drug candidate bites the dust...Unfortunate, really wish there was a good drug to help these pts. $CA…
RT @JohnCendpts: Catabasis shares are shredded after lead drug flops in PhII Duchenne MD study
$CATB -65% $SRPT
https://t.co/kZ1X4MQ4Lh
That was the hope/projection $SRPT https://t.co/82bRTHc3ch
$SRPT well over $1b in sales in a few years, this stock could go against this call in a meaningful way...
$SRPT - here's the rub - tricky to make a bear call given the potential upside if he's wrong - given that he thinks… https://t.co/jqSlZKfYz4
$SRPT - to be fair, it was a well conducted survey and being the good analyst he is (and i mean that, Joe is generally very good and v smart
@abbynach that's first hand research. Bravo. But sucks for $SRPT.
$SRPT - also he says "there are many reasons to question the pushback will dissipate - that is based on current information...hmmm
@BiotechHack Survey with payors, whom are eager to cooperate.. $SRPT
$SRPT - so the bet here is that SRPT sees a 62% coverage rate this year vs. his estimates of 54% - if his margin of error is off, then what?
$SRPT he then says other candidates will be approved and those should generate $200m each
@jq1234t yeah Approve, like the scam $SRPT, then PBMs won't reimburse, else non-profit charities take the tab/NOT taxpayers paying shit bios
$SRPT So what i find funny is that Joe's numbers and mine arent all that far apart - in fact, his $800m 2024 sales is probability weighted
@BiotechHack BUZZKILL $SRPT
$SRPT Joe Schwartz from Leerink published a bearish report tonight - here's the thesis .... https://t.co/HGmTuD3o4m
EMA starting date is December 20, 2016 so that means that 210 days later would be July 18, 2017. $SRPT
RT @BiotechSage: @BiotechSage Leerink asserts that payors are denying coverage more often than providing it $SRPT https://t.co/qeTV4oGvFS
$SRPT showed strength today good close, may break downward trend this week. https://t.co/egmHOZSMf9
@jeffrgordon comment is without context. $srpt said of the 250 Q4 starts they expect the majority of them to rec. coverage in '17
RT @upsidetrader: $SRPT falling wedge breakout, good volume https://t.co/HsL8hgsvuL
RT @upsidetrader: $SRPT falling wedge breakout, good volume https://t.co/HsL8hgsvuL
$SRPT in #srpt again at $30.83 PPS I buy in tranches, works for me. PT $110 PPS Mark This Post Bullish & #ComeFollowMe into a green 2017
RT @RGstocktrader: $srpt $rlyp all over again... https://t.co/bYwn9inThn
Another Duchenne's drug candidate bites the dust...Unfortunate, really wish there was a good drug to help these pts. $CATB $BMRN $SRPT $PTCT
RT @BiotechSage: @BiotechSage Leerink asserts that payors are denying coverage more often than providing it $SRPT https://t.co/qeTV4oGvFS
@BiotechSage Leerink 2nd bullet, when did $SRPT say that for 2017? Implies >1000 kids on drug. Then says 1 in 5 agree. If so, PPS>$100
RT @upsidetrader: $SRPT falling wedge breakout, good volume https://t.co/HsL8hgsvuL
RT @BiotechSage: @BiotechSage Leerink asserts that payors are denying coverage more often than providing it $SRPT https://t.co/qeTV4oGvFS
RT @Quarry_Rock: $SRPT ...OH BOY! if they get over $40 again shorts calling home to momma collect ...
$SRPT ...OH BOY! if they get over $40 again shorts calling home to momma collect ...
RT @upsidetrader: $SRPT falling wedge breakout, good volume https://t.co/HsL8hgsvuL
@Lblegend33 @BiotechSage yes, is exactly consistent w what has been stated by Kaye, ie "79% are pending policy decision" $srpt #exondys51
DNP, "You're Fired" $SRPT https://t.co/4OWrDO7bYY
RT @upsidetrader: $SRPT falling wedge breakout, good volume https://t.co/HsL8hgsvuL
RT @BiotechSage: @BiotechSage Leerink asserts that payors are denying coverage more often than providing it $SRPT https://t.co/qeTV4oGvFS
RT @BiotechSage: @BiotechSage Leerink asserts that payors are denying coverage more often than providing it $SRPT https://t.co/qeTV4oGvFS
$SRPT falling wedge breakout, good volume https://t.co/HsL8hgsvuL
@BiotechSage why the hell is he increasing his estimates considering his bearish view? $SRPT
RT @BiotechSage: @BiotechSage Leerink asserts that payors are denying coverage more often than providing it $SRPT https://t.co/qeTV4oGvFS
@BiotechSage Leerink asserts that payors are denying coverage more often than providing it $SRPT https://t.co/qeTV4oGvFS
RT @JohnCendpts: Catabasis shares are shredded after lead drug flops in PhII Duchenne MD study
$CATB -65% $SRPT
https://t.co/kZ1X4MQ4Lh
@BiotechSage Is Joey accusing himself of misinterpreting facts provided by management? Or accusing management of lying? $SRPT
RT @BiotechSage: Leerink on $SRPT "MEDACorp survey suggests that the reimbursement landscape for Exondys51 is more tenuous than mgmt. indi…
RT @BiotechSage: Leerink on $SRPT "MEDACorp survey suggests that the reimbursement landscape for Exondys51 is more tenuous than mgmt. indi…
Leerink on $SRPT "MEDACorp survey suggests that the reimbursement landscape for Exondys51 is more tenuous than mgmt. indicated recently
RT @JohnCendpts: Catabasis shares are shredded after lead drug flops in PhII Duchenne MD study
$CATB -65% $SRPT
https://t.co/kZ1X4MQ4Lh
RT @upsidetrader: $SRPT falling wedge breakout, good volume https://t.co/HsL8hgsvuL
Bullish Engulfing https://t.co/CZxCmhnevl $IJH $ARNA $GERN $SRPT $PFE $TJX $SYMC $UTX $EXC $DYN $TNK $CSC $ARNC $HPE $IRWD $PANW $VIAV
@BiotechHack majority of these payers will break with a move in price. $SRPT will win, just a matter of by how much
Auto-trading subcriptions available at Profectus Systems: $REXX $WLL $SRPT $GALE $XOM $F $GM $NKE $SBUX $FCX $LUV $AAL $PZZA $DPZ
Snippet from Leerink note on $SRPT : lowering value of a priority review voucher $350m>$200m. $ABBV, as usual, bought at top.
Bullish Engulfing https://t.co/CZxCmhnevl $IJH $ARNA $GERN $SRPT $PFE $TJX $SYMC $UTX $EXC $DYN $TNK $CSC $ARNC $HPE $IRWD $PANW $VIAV
RT @_B_I_O_T_E_C_H_: Leerink $SRPT PT to $32 - Payor Survey Suggests Limited Early Coverage of Exondys51, Headwinds to Growth • (cont) http…
RT @JacobPlieth: Leerink cuts expected value of $SRPT PRV from $350m to $200m to reflect fall in scarcity value & limited benefit realised…
$SRPT "Exondys51 Faces Unique #Hurdles in DMD The KOL treats 80-90 boys with DMD in her clinic where (cont) https://t.co/9hClgx00LY
Leerink $SRPT PT to $32 - Payor Survey Suggests Limited Early Coverage of Exondys51, Headwinds to Growth • (cont) https://t.co/ES6Qjnqi0A
RT @upsidetrader: $SRPT falling wedge breakout, good volume https://t.co/HsL8hgsvuL
Leerink cuts expected value of $SRPT PRV from $350m to $200m to reflect fall in scarcity value & limited benefit realised by $REGN
RT @JacobPlieth: Leerink MEDACorp payor survey suggests $SRPT Exondys51 reimbursement is more tenuous than mgm indicated recently; risk to…
Leerink MEDACorp payor survey suggests $SRPT Exondys51 reimbursement is more tenuous than mgm indicated recently; risk to consensus in 2017
this $SRPT KOL bashing of $PTCT Ataluren in DMD its killing me. https://t.co/aHEejqTWy9
@BiotechHack I have 2024 Revs. a few @OMillionaires more than that! $SRPT
paid $SRPT KOLs like this lady https://t.co/g1FqE7IQBh understand that $PTCT ORAL exon skipping drugs may be biggest competitor to $SRPT
is this even ethical? for $SRPT KOL, for a drug that was never tested properly to shed skepticism n $PTCT that trea… https://t.co/9E3DMopkgW